350 related articles for article (PubMed ID: 10807491)
1. Evidence of the dual mechanisms of action of venlafaxine.
Harvey AT; Rudolph RL; Preskorn SH
Arch Gen Psychiatry; 2000 May; 57(5):503-9. PubMed ID: 10807491
[TBL] [Abstract][Full Text] [Related]
2. Differential physiological effects of a low dose and high doses of venlafaxine in major depression.
Debonnel G; Saint-André E; Hébert C; de Montigny C; Lavoie N; Blier P
Int J Neuropsychopharmacol; 2007 Feb; 10(1):51-61. PubMed ID: 16690006
[TBL] [Abstract][Full Text] [Related]
3. Effects of different doses of venlafaxine on serotonin and norepinephrine reuptake in healthy volunteers.
Blier P; Saint-André E; Hébert C; de Montigny C; Lavoie N; Debonnel G
Int J Neuropsychopharmacol; 2007 Feb; 10(1):41-50. PubMed ID: 16690005
[TBL] [Abstract][Full Text] [Related]
4. Differential Potency of Venlafaxine, Paroxetine, and Atomoxetine to Inhibit Serotonin and Norepinephrine Reuptake in Patients With Major Depressive Disorder.
Aldosary F; Norris S; Tremblay P; James JS; Ritchie JC; Blier P
Int J Neuropsychopharmacol; 2022 Apr; 25(4):283-292. PubMed ID: 34958348
[TBL] [Abstract][Full Text] [Related]
5. Venlafaxine: discrepancy between in vivo 5-HT and NE reuptake blockade and affinity for reuptake sites.
Béïque JC; de Montigny C; Blier P; Debonnel G
Synapse; 1999 Jun; 32(3):198-211. PubMed ID: 10340630
[TBL] [Abstract][Full Text] [Related]
6. In vitro effects of serotonin and noradrenaline reuptake inhibitors on human platelet adhesion and coagulation.
Hallbäck I; Hägg S; Eriksson AC; Whiss PA
Pharmacol Rep; 2012; 64(4):979-83. PubMed ID: 23087151
[TBL] [Abstract][Full Text] [Related]
7. Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects.
Turcotte JE; Debonnel G; de Montigny C; Hébert C; Blier P
Neuropsychopharmacology; 2001 May; 24(5):511-21. PubMed ID: 11282251
[TBL] [Abstract][Full Text] [Related]
8. Blockade of 5-hydroxytryptamine and noradrenaline uptake by venlafaxine: a comparative study with paroxetine and desipramine.
Béïque JC; de Montigny C; Blier P; Debonnel G
Br J Pharmacol; 1998 Oct; 125(3):526-32. PubMed ID: 9806336
[TBL] [Abstract][Full Text] [Related]
9. Effects of sustained administration of the serotonin and norepinephrine reuptake inhibitor venlafaxine: II. In vitro studies in the rat.
Béïque J; de Montigny C; Blier P; Debonnel G
Neuropharmacology; 2000 Jul; 39(10):1813-22. PubMed ID: 10884562
[TBL] [Abstract][Full Text] [Related]
10. Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats.
Koch S; Hemrick-Luecke SK; Thompson LK; Evans DC; Threlkeld PG; Nelson DL; Perry KW; Bymaster FP
Neuropharmacology; 2003 Dec; 45(7):935-44. PubMed ID: 14573386
[TBL] [Abstract][Full Text] [Related]
11. Effects of sustained administration of the serotonin and norepinephrine reuptake inhibitor venlafaxine: I. in vivo electrophysiological studies in the rat.
Béïque J; de Montigny C; Blier P; Debonnel G
Neuropharmacology; 2000 Jul; 39(10):1800-12. PubMed ID: 10884561
[TBL] [Abstract][Full Text] [Related]
12. Antidepressants that inhibit both serotonin and norepinephrine reuptake impair long-term potentiation in hippocampus.
Cooke JD; Cavender HM; Lima HK; Grover LM
Psychopharmacology (Berl); 2014 Dec; 231(23):4429-41. PubMed ID: 24781518
[TBL] [Abstract][Full Text] [Related]
13. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.
Ball SE; Ahern D; Scatina J; Kao J
Br J Clin Pharmacol; 1997 Jun; 43(6):619-26. PubMed ID: 9205822
[TBL] [Abstract][Full Text] [Related]
14. PET neuroimaging with [11C]venlafaxine: serotonin uptake inhibition, biodistribution and binding in living pig brain.
Smith DF; Jensen PN; Gee AD; Hansen SB; Danielsen E; Andersen F; Saiz PA; Gjedde A
Eur Neuropsychopharmacol; 1997 Aug; 7(3):195-200. PubMed ID: 9213078
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of uptake 2 (or extraneuronal monoamine transporter) by normetanephrine potentiates the neurochemical effects of venlafaxine.
Rahman Z; Ring RH; Young K; Platt B; Lin Q; Schechter LE; Rosenzweig-Lipson S; Beyer CE
Brain Res; 2008 Apr; 1203():68-78. PubMed ID: 18321472
[TBL] [Abstract][Full Text] [Related]
16. Effects of acute treatment with paroxetine, citalopram and venlafaxine in vivo on noradrenaline and serotonin outflow: a microdialysis study in Swiss mice.
David DJ; Bourin M; Jego G; Przybylski C; Jolliet P; Gardier AM
Br J Pharmacol; 2003 Nov; 140(6):1128-36. PubMed ID: 14530210
[TBL] [Abstract][Full Text] [Related]
17. [Psychopharmacological profile of venlafaxine].
Bourin M
Encephale; 1999 Jun; 25 Spec No 2():21-2; discussion 23-5. PubMed ID: 10434156
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the effects of serotonin selective, norepinephrine selective, and dual serotonin and norepinephrine reuptake inhibitors on lower urinary tract function in cats.
Katofiasc MA; Nissen J; Audia JE; Thor KB
Life Sci; 2002 Aug; 71(11):1227-36. PubMed ID: 12106588
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the effects of antidepressants on norepinephrine and serotonin concentrations in the rat frontal cortex: an in-vivo microdialysis study.
Beyer CE; Boikess S; Luo B; Dawson LA
J Psychopharmacol; 2002 Dec; 16(4):297-304. PubMed ID: 12503828
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous increases of extracellular monoamines in microdialysates from hypothalamus of conscious rats by duloxetine, a dual serotonin and norepinephrine uptake inhibitor.
Engleman EA; Perry KW; Mayle DA; Wong DT
Neuropsychopharmacology; 1995 Jul; 12(4):287-95. PubMed ID: 7576005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
